Abstract
IMROZ represents a landmark study in multiple myeloma and is the first global Phase III study of an anti-CD38 monoclonal antibody (mAb) in combination with standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) to show a significant improvement in progression-free survival (PFS), together with deep and sustained responses, in newly-diagnosed patients not intended for transplant. During a joint interview conducted by the European Medical Journal (EMJ), two leading experts in the field of myeloma and co-investigators on the IMROZ study, Meral Beksac from the Division of Haematology, Ankara Liv Hospital Istinye University, Türkiye; and Mohamad Mohty from Sorbonne University, Saint-Antoine Hospital, Paris, France, discussed the findings and clinical implications of this important study of the isatuximab (Isa) plus VRd regimen. Beksac and Mohty reviewed the methodology and key efficacy and safety data from the IMROZ trial, and offered their perspectives on evaluating patient eligibility for haematopoietic stem cell transplantation (HSCT). The experts also considered the clinical impact of IMROZ on the management of newly diagnosed myeloma, and the potential positioning of quadruplet regimens such as Isa-VRd as the new first-choice frontline treatment for transplant-ineligible patients.